Does Dr. PETER ABDELMESSIEH have financial conflicts of interest?

Dr. PETER ABDELMESSIEH (DO) has received a total of $7,325 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $7,325 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. PETER ABDELMESSIEH?

According to CMS Open Payments data, Dr. PETER ABDELMESSIEH received funding from AMGEN ($4,522), CTI BIOPHARMA ($1,725), and GLAXOSMITHKLINE ($430).

Does Dr. PETER ABDELMESSIEH receive research grants or speaking fees?

Dr. PETER ABDELMESSIEH has received $7,325 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. PETER ABDELMESSIEH

DOReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: ROBBINSVILLE, NJ 08691

NPI Number: 1073803896

LIFETIME INDUSTRY VALUE

$7,325

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDELMESSIEH is a verified Internal Medicine, Medical Oncology practitioner based in ROBBINSVILLE, NJ.

Between 2021 and 2024, Dr. ABDELMESSIEH had an overall industry promotional and research financial footprint of $7,325 as recorded in the federal CMS Open Payments database.

$7,325 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDELMESSIEH's primary funding source is AMGEN, which accounts for $4,522 (representing 61.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

AMGEN

Rank 1

$4,522

61.7%

CTI BIOPHARMA

Rank 2

$1,725

23.5%

GLAXOSMITHKLINE

Rank 3

$430

5.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.